Clinical Trials

Norrsken VC

Check: Norrsken VC currently states €1M–€10M early-stage and growth tickets. This is the firm's range, not Tove's personal promise. Confirm initial ticket, follow-on reserves, ownership and stage with the team.

Tove backs ambitious European technology companies whose commercial growth directly improves outcomes for people or planet. Her Bain private-equity background and early impact roles add rigorous market and diligence discipline. Current health-AI work highlights companies that combine deep sector expertise, proprietary data and measurable time or cost improvements in critical systems such as clinical trials.

Norrsken Impact Fund

Check: Historical Norrsken role. The firm now publishes €1M–€10M tickets, but no personal ticket or present investing authority should be inferred because Christian left for an operating role in 2026.

During his Norrsken tenure, Christian explored frontier technologies where difficult physical environments create enabling infrastructure for Earth: satellites for climate intelligence, microgravity for drugs, semiconductors and materials, and in-space supply chains. His move to Biorce shifts his current work from capital allocation to operating an AI clinical-trial platform.

First Round Capital

Check: First Round's published firm-wide initial checks are typically $1M–$7M, averaging about $3.5M; it has participated in rounds from $100K to $20M. No personal range is published for Hayley.

Hayley backs very early founders tackling real-world systems—especially healthcare, climate, supply chain, and commerce—that have been overlooked or written off as unsolvable. As a former founder, she evaluates both halves of the journey: the cold mechanics of execution and the emotional endurance of company-building, combining data-driven precision with direct, empathetic support.

Khosla Ventures

Check: No reliable current personal check range was found. Khosla Ventures invests across company stages and is known for both early technical risk and later follow-on support, but founders should ask Jun about the applicable vehicle, initial ownership, reserves and decision process rather than relying on marketplace estimates.

Jun backs long-horizon technologies at the intersection of biology, healthcare and frontier engineering. His medical training, decade of bench and clinical research, digital-health operating work and company-formation experience support a first-principles lens: take technically difficult risks where a validated breakthrough could materially improve health, then confront clinical evidence, affordability, access, regulation and real-world adoption early.